ATXS

Astria Therapeutics, Inc. [ATXS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ATXS Stock Summary

Top ATXS Correlated Resources

ATXS

Top 10 Correlated ETFs

ATXS

Top 10 Correlated Stocks

ATXS

In the News

ATXS Financial details

Company Rating
-
Market Cap
593.5M
Income
-70.59M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.32
Forward P/E
-
PEG
1.27
P/S
-
P/B
1.2
P/C
-
P/FCF
-5.88
Quick Ratio
20.12
Current Ratio
20.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
-29.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
36.51%
-
-
-
-
SMA20
-38.04%
SMA50
-46.06%
SMA100
-59.03%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-25%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.26-16.9
52W High
-74.31%
52W Low
+2.75%
RSI
30.88
Rel Volume
0.43
Avg Volume
1.04M
Volume
450.45K
Perf Week
0.74%
Perf Month
-33.6%
Perf Quarter
-64.81%
Perf Half Y
-63.5%
-
-
-
-
Beta
0.707
-
-
Volatility
0.07%, 1.05%
Prev Close
1.73%
Price
4.11
Change
3.53%

Something similar

Top by Market Cap
BRK-A
MIX.JO
V
MSFT
ABEC.DE
Top Correlated ETFs
HMMJ.TO
EALU.MI
2CAR.MI
BIB
FTXH
Top Correlated Stocks
CMCM
TUYA
CNDT
WB
WVE
Similar Market Cap
AIRX.OL
SUSB
ONEY
3018.TW
FCEL

Company Profile

Healthcare Biotechnology
  • Volume Average 1.04M
  • Market Capitalization 593.5M
  • Employee 59
  • CEO Ms. Jill C. Milne Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2015-06-25
  • Website https://www.astriatx.com

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.